Dennis Ding
Stock Analyst at Jefferies
(3.86)
# 1,940
Out of 5,108 analysts
87
Total ratings
50.6%
Success rate
9.1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Dennis Ding
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PCRX Pacira BioSciences | Downgraded: Hold | $36 | $36.43 | -1.18% | 1 | Oct 8, 2026 | |
| ROIV Roivant Sciences | Reiterated: Buy | $42 → $52 | $38.88 | +33.74% | 18 | Sep 8, 2026 | |
| TARS Tarsus Pharmaceuticals | Reiterated: Buy | $105 | $68.60 | +53.06% | 1 | Sep 8, 2026 | |
| KARD Kardigan | Initiated Coverage: Buy | $40 | $15.52 | +157.73% | 1 | Jul 13, 2026 | |
| TSX: APTX Apotex Health Corp. | Initiated Coverage: Buy | $40.00 | $34.48 | +16.01% | 1 | Jul 6, 2026 | |
| ARDX Ardelyx | Reiterated: Buy | $15 | $2.88 | +420.83% | 7 | Jun 26, 2026 | |
| RYTM Rhythm Pharmaceuticals | Reiterated: Buy | $125 | $112.28 | +11.33% | 10 | Jun 15, 2026 | |
| SGP SpyGlass Pharma | Reiterated: Buy | $62 | $36.95 | +67.82% | 4 | May 19, 2026 | |
| AMPH Amphastar Pharmaceuticals | Downgraded: Hold | $22 | $28.49 | -22.78% | 1 | Apr 21, 2026 | |
| OLMA Olema Pharmaceuticals | Initiated Coverage: Buy | $40 | $7.33 | +445.70% | 1 | Mar 19, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7 | $3.66 | +91.52% | 4 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $15 → $26 | $15.33 | n/a | 5 | Sep 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $45 | $18.90 | n/a | 14 | Jun 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $20 → $18 | $30.53 | n/a | 2 | May 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $8 | $1.50 | n/a | 1 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $35 | $20.42 | n/a | 1 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $8 → $6 | $3.52 | n/a | 2 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $1 | $2.12 | n/a | 2 | Jul 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $2,275 → $70 | $15.07 | n/a | 4 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $18 | $0.9578 | n/a | 3 | Jul 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $35 → $22 | $72.77 | n/a | 4 | Feb 14, 2023 |
Pacira BioSciences
Oct 8, 2026
Downgraded: Hold
Price Target: $36
Current: $36.43
Upside: -1.18%
Roivant Sciences
Sep 8, 2026
Reiterated: Buy
Price Target: $42 → $52
Current: $38.88
Upside: +33.74%
Tarsus Pharmaceuticals
Sep 8, 2026
Reiterated: Buy
Price Target: $105
Current: $68.60
Upside: +53.06%
Kardigan
Jul 13, 2026
Initiated Coverage: Buy
Price Target: $40
Current: $15.52
Upside: +157.73%
Apotex Health Corp.
Jul 6, 2026
Initiated Coverage: Buy
Price Target: $40.00
Current: $34.48
Upside: +16.01%
Ardelyx
Jun 26, 2026
Reiterated: Buy
Price Target: $15
Current: $2.88
Upside: +420.83%
Rhythm Pharmaceuticals
Jun 15, 2026
Reiterated: Buy
Price Target: $125
Current: $112.28
Upside: +11.33%
SpyGlass Pharma
May 19, 2026
Reiterated: Buy
Price Target: $62
Current: $36.95
Upside: +67.82%
Amphastar Pharmaceuticals
Apr 21, 2026
Downgraded: Hold
Price Target: $22
Current: $28.49
Upside: -22.78%
Olema Pharmaceuticals
Mar 19, 2026
Initiated Coverage: Buy
Price Target: $40
Current: $7.33
Upside: +445.70%
Dec 11, 2025
Reiterated: Buy
Price Target: $7
Current: $3.66
Upside: +91.52%
Sep 3, 2025
Reiterated: Hold
Price Target: $15 → $26
Current: $15.33
Upside: n/a
Jun 11, 2025
Reiterated: Buy
Price Target: $45
Current: $18.90
Upside: n/a
May 29, 2025
Reiterated: Hold
Price Target: $20 → $18
Current: $30.53
Upside: n/a
Nov 7, 2024
Initiated Coverage: Buy
Price Target: $8
Current: $1.50
Upside: n/a
Sep 19, 2024
Upgraded: Buy
Price Target: $35
Current: $20.42
Upside: n/a
Sep 3, 2024
Reiterated: Hold
Price Target: $8 → $6
Current: $3.52
Upside: n/a
Jul 17, 2024
Reiterated: Hold
Price Target: $1
Current: $2.12
Upside: n/a
Jun 17, 2024
Downgraded: Hold
Price Target: $2,275 → $70
Current: $15.07
Upside: n/a
Jul 13, 2023
Reiterated: Buy
Price Target: $18
Current: $0.9578
Upside: n/a
Feb 14, 2023
Rated: Hold
Price Target: $35 → $22
Current: $72.77
Upside: n/a